Goepfert, P., Elizaga, M., Montefiori, D., Hural, J., DeRosa, S., Tomaras, G., … Robinson, H. (2012). Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles. In Retrovirology (Vol. 9). Springer Science and Business Media LLC. https://doi.org/10.1186/1742-4690-9-s2-o56

Goepfert, P., M. Elizaga, D. Montefiori, J. Hural, S. DeRosa, G. Tomaras, K. Seaton, et al. “Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles.” In Retrovirology, Vol. 9. Springer Science and Business Media LLC, 2012. https://doi.org/10.1186/1742-4690-9-s2-o56.

Goepfert P, Elizaga M, Montefiori D, Hural J, DeRosa S, Tomaras G, et al. Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles. In: Retrovirology. Springer Science and Business Media LLC; 2012.

Goepfert, P., et al. “Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles.” Retrovirology, vol. 9, no. S2, Springer Science and Business Media LLC, 2012. Crossref, doi:10.1186/1742-4690-9-s2-o56.

Goepfert P, Elizaga M, Montefiori D, Hural J, DeRosa S, Tomaras G, Seaton K, Sato A, Ouedraogo L, Donastorg Y, Cardinali M, Lama J, Baden L, Keefer M, McElrath J, Kalams S, Robinson H. Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles. Retrovirology. Springer Science and Business Media LLC; 2012.